Sarah Gheuens - 02 Dec 2022 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Role: Chief Medical Officer
Signature: /s/ William Cook, as attorney-in-fact for Sarah Gheuens
Issuer symbol: AGIO
Transactions as of: 02 Dec 2022
Net transactions value: -$7,150
Form type: 4
Filing time: 06 Dec 2022, 15:14:19 UTC
Previous filing: 03 Mar 2022
Next filing: 28 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AGIO	Common stock	Options Exercise	$0	+833	+9.9%	$0.000000	9,261	02 Dec 2022	Direct	F1
transaction	AGIO	Common stock	Tax liability	$7,150	-248	-2.7%	$28.83	9,013	06 Dec 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AGIO	Restricted stock units	Options Exercise	$0	-833	-100%	$0.000000^*	0	02 Dec 2022	Common stock	833		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 660 shares purchased through the Company's employee stock purchase plan.
F2	Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F3	The restricted stock units were granted on December 2, 2019. Beginning on December 2, 2020, the shares underlying the restricted stock units will vest in three equal annual installments.